Wird geladen...
Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth
BACKGROUND: Increased exposure to multitargeted kinase inhibitor sunitinib is associated with improved outcome, emphasizing the importance of maintaining adequate dosing and drug levels. The currently approved schedule (50 mg daily, four weeks on, two weeks off) precludes further dose-intensificatio...
Gespeichert in:
| Veröffentlicht in: | J Exp Clin Cancer Res |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BioMed Central
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5013589/ https://ncbi.nlm.nih.gov/pubmed/27604186 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-016-0411-2 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|